QuidelOrtho Corporation (QDEL)

Market Cap	2.08B
Revenue (ttm)	2.76B
Net Income (ttm)	-358.70M
Shares Out	67.63M
EPS (ttm)	-5.33
PE Ratio	n/a
Forward PE	12.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,577
Open	30.82
Previous Close	31.55
Day's Range	30.82 - 30.82
52-Week Range	23.77 - 49.45
Beta	0.07
Analysts	Buy
Price Target	44.43 (+44.16%)
Earnings Date	Jul 30, 2025

About QDEL

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease,...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1979
• Employees: 6,600
• Stock Exchange: NASDAQ
• Ticker Symbol: QDEL
• Website: https://www.quidelortho.com

Financial Performance

In 2024, QuidelOrtho's revenue was $2.78 billion, a decrease of -7.17% compared to the previous year's $3.00 billion. Losses were -$2.05 billion, 20216.8% more than in 2023.

Analyst Summary

According to 7 analysts, the average rating for QDEL stock is "Buy." The 12-month stock price target is $44.43, which is an increase of 44.16% from the latest price.

Price Target

$44.43

(44.16% upside)

Analyst Consensus: Buy